ทวีตที่ปักหมุด
Excited to share our article in @Annals_Oncology about Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)!
@MDAndersonNews @isliquidbiopsy
annalsofoncology.org/article/S0923-…
English
Mohamed A Gouda
603 posts
Mohamed A Gouda
@mgoudaMD
I am a medical oncologist with interest in drug development and biomarker-driven therapies. This is a personal Profile | Views are Mine
Houston, TX เข้าร่วม Eylül 2010
542 กำลังติดตาม1.1K ผู้ติดตาม
Mohamed A Gouda รีทวีตแล้ว
Headed to #AACR26, the same week we had practice changing clinical trial data in #PancreaticCancer with a KRAS inhibitor.
Reminded of this critique that @Pasca_Lab received on her grant in 2013 - "There are not, and will never be, KRAS inhibitors".
Keep calm & science on!
English
I am pleased to share my new appointment as Research Assistant Professor at @OSUCCC_James 🙌
The academic environment at #OSU is exceptional for advancing oncology research!
Special thanks to my mentor @ChristianRolfo for guiding me in my research journey! 🩸🧬
@rolfolab
English
Mohamed A Gouda รีทวีตแล้ว
⭐️🚨 🧬 Hot off the press 👉🏼A new chapter in cancer biology’s foundational text 👉🏼
🚨Hanahan’s “Hallmarks of Cancer-Then and Now, and Beyond” drops in @CellCellPress updating the framework that has shaped 25 years of oncology research, precision oncology & clinical trials
The roadmap evolves. Required reading @OncoAlert 📌
cell.com/cell/fulltext/…
English
✨Grateful to step into the role of Chief of Thoracic Medical Oncology at Baptist Health Miami Cancer Institute. Thank you to #DrLeonardKalman and #ManmeetAhluwalia
for the trust and opportunity. Looking forward to building and growing a strong, impactful Thoracic Oncology program. @BaptistHealthSF @MiamiCancerInst
baptisthealth.net/newsroom/press…
English
Mohamed A Gouda รีทวีตแล้ว
Mohamed A Gouda รีทวีตแล้ว
💣 Important Shift in Cytopenia Grading: CTCAE v6.0 Update
If you are a PI running #Hematology or #Oncology trials, note these key changes in the new CTCAE v6.0 vs v5.0:
📉 General Trend: "Downgrading" of severity. Many counts that were previously Grade 3/4 are now lower grades.
🧪 Neutrophils:
Grade 1 Gone: ANC 1000–1500 is now Grade 1 (was G2). The old Grade 1 (1500–LLN) is no longer graded.
Stricter G4: threshold drops from <500 to <100/mm³.
🩸 Platelets (Thrombocytopenia):
Wider G3: Now covers 10k–50k (previously 25k–50k).
Stricter G4: threshold drops from <25k to <10k/mm³.
v6.0 also adds "transfusion indicated" to Grade 3 and "urgent intervention indicated" to Grade 4 criteria.
Overall, IMO these new thresholds align better with clinical practice.
#ClinicalTrials #MedEd #OncTwitter #DrugSafety
English
Important to recognize the top reason is not that the drug didn't work! @DavidHongMD used to tell us in clinic about molecules that were potentially effective but sadly discontinued. Enforcing publication of data from terminated trials is important for future generations!
Vivek Subbiah, MD@VivekSubbiah
Analysis of phase II and phase III clinical trial terminations from 2013 to 2023 nature.com/articles/d4157…
English
Important article! Sadly, equally important (and less discussed) is overlooking poorly conducted systematic reviews and meta-analyses. Despite being atop the evidence pyramid, some are pursued by students/trainees as an easy way of publishing - often without the rigor required!
Samer Al Hadidi, MD,MS,FACP@HadidiSamer
Check our viewpoint published @JAMA_current #MedEd Abstract Factory—Research Culture Harming Medical Education The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor. ➡️jamanetwork.com/journals/jama/… @utswcancer @rajshekharucms @HiraSMian @ManniMD1 @HemOncFellows @ASCOTECAG
English
Truly humbled by the support of colleagues across the American Society of Clinical Oncology (@ASCO) global community. Thank you for the trust and encouragement—I’m deeply grateful and excited to serve. @OncoAlert @urotoday @OncBrothers @montypal @DrChoueiri @DrRanaMcKay
Neeraj Agarwal, MD, FASCO@neerajaiims
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit asco.org/election to learn more about the candidates and place your vote! Thank you!!
English
Mohamed A Gouda รีทวีตแล้ว
In 6 of 14 patients receiving immune checkpoint inhibitors, cell-free DNA methylation profiling revealed multiorgan damage with immune-related adverse events, often before symptoms appeared. Learn more: nej.md/4907cG5
English
I matched Cardiology at Brigham and Women's Hospital @BrighamFellows
Could not have done this without the support of my program leadership @TradIMYale and mentors; eternally grateful 💝💝
A simple kid from Egypt is going from Yale (IM) to Harvard (Cardiology). What a journey!
English
Mohamed A Gouda รีทวีตแล้ว
Shall y’all be prepared after Thanksgiving week! @AhnertJord67866 @DavidHongMD @DrMirallas @DanielHaldarMD @DrShubhamPant @DanZhaoMD @drsmags @mirella_nardo @CarlosTorradoMD @mgoudaMD @JavleMilind @Fen_Saj @GarridoLagunaMD @jpshen_md @Guv_onc @VanMorrisMD @jtmoyers @NatalieNgoi
#TumorBoardTuesday@TumorBoardTues
@SagarRPatelMD @UroDocAsh @MDAndersonNews @IntegrityCE #tumorboardtuesday 🙏Thank you @UroDocAsh & @SagarRPatelMD for a great lesson on local Tx for NMIBC 📢And join us for another session of @TumorBoardTues next week, 12/02/2025 as @AhnertJord67866 & @CamilaBragancaX teach us all about PRMT5 Inhibition for MTAP-deleted PDAC
English
#Tenure! I’m overwhelmed with gratitude to share that I’ve been awarded tenure at @WeillCornell @Cornell
I’m deeply grateful to my family, mentors, collaborators, and the many friends and colleagues in the field who have supported me in so many ways over the years. Too many names to list here! Thank you to every single one of you.
To the #FaltasLab members and alumni, your creativity, persistence, and teamwork made this possible. You’ve made me better in every way, and it’s a privilege to witness your growth and successes. This truly belongs to all of you.
As I reflect on this journey, I’m reminded of the challenges we’ve overcome, and of the profound privilege of being a physician-scientist: caring for patients with #bladdercancer, doing cutting-edge science, and mentoring the next generation of bright minds.
The next chapter is about asking bigger questions and building new bridges, between science and medicine, and between people! @WCMEnglanderIPM @WCM_MeyerCancer
With passion, persistence, and humility, onward!
English
Mohamed A Gouda รีทวีตแล้ว
🚨Our new paper is out today in Nature! We show that SARS-CoV-2 mRNA vaccines can sensitize tumors to immune checkpoint blockade (ICI) — revealing that clinically available RNA vaccines may act as potent immune modulators. nature.com/articles/s4158…
English
And in a retrospective study, we looked into correlations between formula based calculated creatinine clearance and actual 24H creatinine clearance (allowed in only 20% of trial protocols)! @DavidHongMD
English
In NCI10220 BeGIN trial, we reported outcome data from utilizing glutaminase inhibition in molecularly selected cohorts with NF1, KEAP1/NRF2, and STK11/LKB1 alterations @VivekSubbiah
English
Mohamed A Gouda รีทวีตแล้ว
Very important data on the application of liquid biopsy in clinical practice.
@isliquidbiopsy
Tom Powles@tompowles1
1/4 IMVIGOR011 shows ctDNA is a useful predictive and prognostic tool post cystectomy in muscle invasive bladder cancer #ESMO25 . ctDNA positive patients had DFS and OS benifits with atezolizumab. ctDNA negative patients are at a low risk of relapse/cancer death. @OncoAlert
English
Mohamed A Gouda รีทวีตแล้ว
IMA203 showing great promise in both cutaneous #melanoma and #uvealmelanoma. T cell therapy for solid tumors (even “cold” tumors) provides great promise to our patients. Phase 3 cutaneous/acral trial is open at @StanfordCancer @StanfordMed & uveal ph 2 expansion is coming soon!
Toni Choueiri, MD@DrChoueiri
@HaanenJohn distills with a data-driven pitch-perfect analysis of IMA203 in mUM. Reality check: UM → >90% liver mets, ICIs underwhelm (ORR 6–12%); tebentafusp delivers OS in HLA-A+, PRAME-TCR shows striking liver shrinkage (cORR 67%). #ESMO25 @myESMO @Annals_Oncology @OncoAlert @OncLive @DanaFarber
English
Mohamed A Gouda รีทวีตแล้ว
Honored to present #ESMO25 results of Ph3 RELATIVItY-098 w extensive biomarker analyses. Addition of LA3 blockade does not add clinical benefit to PD1 blockade in adjuvant setting. Confirming presence of tumor is critical & validates neoadjuvant approach nature.com/articles/s4159…
English